Dr. Callander on Treatment Considerations in Multiple Myeloma
Natalie S. Callander, MD
Published: Monday, Oct 09, 2017
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.
There are 3 principles to keep in mind when treating patients with relapsed or refractory multiple myeloma, says Callander.
The first is to determine where the patient is in their relapse, the second is to evaluate what type of myeloma the patient has, and the final thing is to consider frailty.
SELECTED LANGUAGE
Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.
There are 3 principles to keep in mind when treating patients with relapsed or refractory multiple myeloma, says Callander.
The first is to determine where the patient is in their relapse, the second is to evaluate what type of myeloma the patient has, and the final thing is to consider frailty.